23 related articles for article (PubMed ID: 38507054)
1. Performance of LI-RADS category 5 vs combined categories 4 and 5: a systemic review and meta-analysis.
Lee S; Kim YY; Shin J; Shin H; Sirlin CB; Chernyak V
Eur Radiol; 2024 May; ():. PubMed ID: 38809263
[TBL] [Abstract][Full Text] [Related]
2. Outcomes in Patients with Macrotrabecular-Massive-Subtype Hepatocellular Carcinoma Treated with Yttrium-90 Transarterial Radioembolization.
Balli HT; Piskin FC; Sozutok S; Erdoğan KE; Aikimbaev K
J Vasc Interv Radiol; 2024 Mar; ():. PubMed ID: 38548131
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Microvascular Invasion and Recurrence After Curative Resection of LI-RADS Category 5 Hepatocellular Carcinoma on Gd-BOPTA Enhanced MRI.
Zhang J; Li Y; Xia J; Pan X; Lu L; Fu J; Jia N
J Hepatocell Carcinoma; 2024; 11():941-952. PubMed ID: 38813100
[TBL] [Abstract][Full Text] [Related]
4. Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS.
Cannella R; Dioguardi Burgio M; Beaufrère A; Trapani L; Paradis V; Hobeika C; Cauchy F; Bouattour M; Vilgrain V; Sartoris R; Ronot M
JHEP Rep; 2021 Dec; 3(6):100380. PubMed ID: 34825155
[TBL] [Abstract][Full Text] [Related]
5. Comparison of imaging findings of macrotrabecular-massive hepatocellular carcinoma using CT and gadoxetic acid-enhanced MRI.
Cha H; Choi JY; Park YN; Han K; Jang M; Kim MJ; Park MS; Rhee H
Eur Radiol; 2023 Feb; 33(2):1364-1377. PubMed ID: 35999373
[TBL] [Abstract][Full Text] [Related]
6. Comparison of computed tomography and magnetic resonance imaging findings and histopathological features of macrotrabecular-massive hepatocellular carcinoma.
Gong Q; Zhang Y; Wu T; Du Z; Zhang Y
Quant Imaging Med Surg; 2023 Jul; 13(7):4633-4640. PubMed ID: 37456331
[TBL] [Abstract][Full Text] [Related]
7. Evaluation and Prognostication of Gd-EOB-DTPA MRI and CT in Patients With Macrotrabecular-Massive Hepatocellular Carcinoma.
Cheng J; Li X; Wang L; Chen F; Li Y; Zuo G; Pei M; Zhang H; Yu L; Liu C; Wang J; Han Q; Cai P; Li X
J Magn Reson Imaging; 2024 Jun; 59(6):2071-2081. PubMed ID: 37840197
[TBL] [Abstract][Full Text] [Related]
8. Macrotrabecular-massive hepatocellular carcinoma: imaging identification and prediction based on gadoxetic acid-enhanced magnetic resonance imaging.
Chen J; Xia C; Duan T; Cao L; Jiang H; Liu X; Zhang Z; Ye Z; Wu Z; Gao R; Shi Y; Song B
Eur Radiol; 2021 Oct; 31(10):7696-7704. PubMed ID: 33856520
[TBL] [Abstract][Full Text] [Related]
9. MRI imaging features for predicting macrotrabecular-massive subtype hepatocellular carcinoma: a systematic review and meta-analysis.
Kim TH; Woo S; Lee DH; Do RK; Chernyak V
Eur Radiol; 2024 Mar; ():. PubMed ID: 38507054
[TBL] [Abstract][Full Text] [Related]
10. Macrotrabecular-Massive Hepatocellular Carcinoma: What Should We Know?
Li X; Yao Q; Liu C; Wang J; Zhang H; Li S; Cai P
J Hepatocell Carcinoma; 2022; 9():379-387. PubMed ID: 35547829
[TBL] [Abstract][Full Text] [Related]
11. Per-Feature Accuracy of Liver Imaging Reporting and Data System Locoregional Treatment Response Algorithm: A Systematic Review and Meta-Analysis.
Huh YJ; Kim DH; Kim B; Choi JI; Rha SE
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503241
[TBL] [Abstract][Full Text] [Related]
12. Tumor in vein (LR-TIV) and liver imaging reporting and data system (LI-RADS) v2018: diagnostic features, pitfalls, prognostic and management implications.
Catania R; Chupetlovska K; Borhani AA; Maheshwari E; Furlan A
Abdom Radiol (NY); 2021 Dec; 46(12):5723-5734. PubMed ID: 34519877
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
